Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factors

被引:4
|
作者
Ye, Yanna [1 ,2 ]
Li, Zhiqiang [1 ]
Kang, Shan [3 ]
Yang, Yongxiu [4 ]
Ling, Bin [5 ]
Wang, Li [6 ]
Yao, Jilong [7 ]
Li, Pengfei [1 ]
Wang, Xueqin [8 ]
Gong, Shipeng [1 ]
Fan, Huijian [9 ]
Kong, Yanxiang [10 ]
Cao, Yuye [1 ]
Lang, Jinghe [1 ,11 ]
Liu, Ping [1 ]
Chen, Chunlin [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, 1838 Guangzhou Ave, Guangzhou 510515, Peoples R China
[2] Dongguan Polytech, Fac Hlth, Dept Midwifery, Dongguan 523000, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Gynecol, Shijiazhuang 050019, Peoples R China
[4] Lanzhou Univ, Hosp 1, Dept Obstet & Gynecol, Lanzhou 730000, Peoples R China
[5] China Japan Friendship Hosp, Dept Obstet & Gynecol, Beijing 100029, Peoples R China
[6] Zhengzhou Univ, Affiliated Canc Hosp, Dept Gynecol Oncol, Zhengzhou 450008, Peoples R China
[7] Shenzhen Maternal & Child Hlth Hosp, Shenzhen 518028, Peoples R China
[8] Southern Med Univ, Affiliated Hosp 5, Dept Obstet & Gynecol, Guangzhou 510920, Peoples R China
[9] Guangzhou Med Univ, Affiliated Hosp 3, Guangzhou 510150, Peoples R China
[10] Sun Yat Sen Univ, Affiliated Hosp 7, Reprod Med Ctr, Shenzhen 518107, Peoples R China
[11] Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing 100193, Peoples R China
关键词
Cervical cancer; FIGO 2018 stage IIIC; Local tumor factors; Treatment; NEOADJUVANT CHEMOTHERAPY; RADICAL HYSTERECTOMY; LYMPH-NODE; METASTASES; CARCINOMA; SURVIVAL; SURGERY; SIZE;
D O I
10.1186/s12885-023-10801-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTo compare the oncological outcomes of patients with FIGO 2018 stage IIIC cervical cancer (CC) involving different local tumor factors who underwent abdominal radical hysterectomy (ARH), neoadjuvant chemotherapy and radical surgery (NACT), or radical chemoradiotherapy (R-CT).MethodsBased on tumor staging, patients with stage IIIC were divided into T1, T2a, T2b, and T3 groups. Kaplan-Meier and Cox proportional hazards regression analysis were used to compare their overall survival (OS) and disease-free survival (DFS) of 5 years.ResultsWe included 4,086 patients (1,117, 1,019, 869, and 1,081 in the T1, T2a, T2b, and T3 groups, respectively). In the T1 group, NACT was correlated with a decrease in OS (hazard ratio [HR] = 1.631, 95% confidence interval [CI]: 1.150-2.315, P = 0.006) and DFS (HR = 1.665, 95% CI: 1.255-2.182, P < 0.001) than ARH. ARH and NACT were not correlated with OS (P = 0.226 and P = 0.921) or DFS (P = 0.343 and P = 0.535) than R-CT. In the T2a group, NACT was correlated with a decrease in OS (HR = 1.454, 95% CI: 1.057-2.000, P = 0.021) and DFS (HR = 1.529, 95% CI: 1.185-1.974, P = 0.001) than ARH. ARH and NACT were not correlated with OS (P = 0.736 and P = 0.267) or DFS (P = 0.714 and P = 0.087) than R-CT. In the T2b group, NACT was correlated with a decrease in DFS (HR = 1.847, 95% CI: 1.347-2.532, P < 0.001) than R-CT nevertheless was not correlated with OS (P = 0.146); ARH was not correlated with OS (P = 0.056) and DFS (P = 0.676). In the T3 group, the OS rates of ARH (n = 10), NACT (n = 18), and R-CT (n = 1053) were 67.5%, 53.1%, and 64.7% (P = 0.941), and the DFS rates were 68.6%, 45.5%, and 61.1%, respectively (P = 0.761).ConclusionR-CT oncological outcomes were not entirely superior to those of NACT or ARH under different local tumor factors with stage IIIC. NACT is not suitable for stage T1, T2a, and T2b. Nevertheless ARH is potentially applicable to stage T1, T2a, T2b and T3. The results of stage T3 require confirmation through further research due to disparity in case numbers in each subgroup.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factors
    Yanna Ye
    Zhiqiang Li
    Shan Kang
    Yongxiu Yang
    Bin Ling
    Li Wang
    Jilong Yao
    Pengfei Li
    Xueqin Wang
    Shipeng Gong
    Huijian Fan
    Yanxiang Kong
    Yuye Cao
    Jinghe Lang
    Ping Liu
    Chunlin Chen
    BMC Cancer, 23
  • [2] Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review
    Qin, Fengying
    Pang, Huiting
    Yu, Tao
    Luo, Yahong
    Dong, Yue
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [3] Validation of the prognostic value of the 2018 FIGO stage IIIC in patients with cervical cancer
    Long, Xingtao
    Zhou, Qi
    Zou, Dongling
    Wang, Dong
    Liu, Jingshu
    Chen, Yuemei
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S329 - S330
  • [4] Rationality of FIGO 2018 IIIC restaging of cervical cancer according to local tumor size: A cohort study
    Duan, Hui
    Li, Huimin
    Kang, Shan
    Zhao, Hongwei
    Chen, Biliang
    Wang, Li
    Li, Pengfei
    Wang, Yahong
    Wang, Wei
    Lang, Jinghe
    Liu, Ping
    Chen, Chunlin
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2023, 102 (08) : 1045 - 1052
  • [5] Significance of tumor size and number of positive nodes in patients with FIGO 2018 stage IIIC1 cervical cancer
    Maeda, Michihide
    Mabuchi, Seiji
    Sakata, Mina
    Deguchi, Satoki
    Kakubari, Reisa
    Matsuzaki, Shinya
    Hisa, Tsuyoshi
    Kamiura, Shoji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (02) : 146 - 152
  • [6] Discussion on the rationality of FIGO 2018 stage IIIC for cervical cancer with oncological outcomes: a cohort study
    Li, Zhiqiang
    Duan, Hui
    Guo, Jianxin
    Yang, Ying
    Wang, Wuliang
    Hao, Min
    Li, Weili
    Li, Pengfei
    Bin, Xiaonong
    Lang, Jinghe
    Liu, Ping
    Chen, Chunlin
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
  • [7] Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical Cancer
    Long, Xingtao
    He, Misi
    Yang, Lingling
    Zou, Dongling
    Wang, Dong
    Chen, Yuemei
    Zhou, Qi
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2023, 17
  • [8] A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System
    Xiaoliang Liu
    Weiping Wang
    Ke Hu
    Fuquan Zhang
    Xiaorong Hou
    Junfang Yan
    Qingyu Meng
    Ziqi Zhou
    Zheng Miao
    Hui Guan
    Jiabin Ma
    Jing Shen
    Hongnan Zhen
    Wenhui Wang
    Scientific Reports, 10
  • [9] A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System
    Liu, Xiaoliang
    Wang, Weiping
    Hu, Ke
    Zhang, Fuquan
    Hou, Xiaorong
    Yan, Junfang
    Meng, Qingyu
    Zhou, Ziqi
    Miao, Zheng
    Guan, Hui
    Ma, Jiabin
    Shen, Jing
    Zhen, Hongnan
    Wang, Wenhui
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14-year multicenter study
    Ye, Yanna
    Zhang, Guozhao
    Li, Zhiqiang
    Chen, Biliang
    Zhao, Hongwei
    Yang, Ying
    Wang, Li
    Yao, Jilong
    Chen, Xiaolin
    Huang, Yahong
    Lang, Jinghe
    Liu, Ping
    Chen, Chunlin
    CANCER MEDICINE, 2023, 12 (19): : 19617 - 19632